Section 8731 - [Effective ninety days following adjournment of the 2024 legislature] DefinitionsAs used in this subchapter, unless the context otherwise indicates, the following terms have the following meanings. [2019, c. 470, §8(NEW).]
1.Brand-name drug. "Brand-name drug" means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product. [2019, c. 470, §8(NEW).]
1-A.Drug product family. "Drug product family" means a group of one or more prescription drugs that share a unique generic drug description and drug form. [2021, c. 305, §1(NEW).]
1-B.Category of insulin. "Category of insulin" means rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin for which at least 2 licenses have been issued by the federal Food and Drug Administration and are actively marketed pursuant to such licensure in a category.2.Generic drug. "Generic drug" means a prescription drug, whether identified by its chemical, proprietary or nonproprietary name, that is not a brand-name drug and is therapeutically equivalent to a brand-name drug in dosage, safety, strength, method of consumption, quality, performance and intended use. "Generic drug" includes a biosimilar product. [2019, c. 470, §8(NEW).]
2-A.Insulin. "Insulin" has the same meaning as in Title 32, section13786-D, subsection 1, paragraph A and includes insulin or an insulin pen that is licensed under the federal Public Health Service Act, 42 United States Code, Section 262(a) or 262(k).3.Manufacturer. "Manufacturer" means an entity that manufactures or repackages, and sets the wholesale acquisition cost for, prescription drugs that are distributed in the State. [2021, c. 305, §2(AMD).]
3-A.Prescription drug. "Prescription drug" means a drug, as defined in 21 United States Code, Section 321(g) or a biological product as defined in 42 United States Code, Section 262(i)(1) that: A. Is intended for human use; [2021, c. 305, §3(NEW).]B. Is not a device within the meaning of 21 United States Code, Section 321(h); and [2021, c. 305, §3(NEW).]C. By federal or state law, can be lawfully dispensed or administered only on prescription by a licensed health care professional. [2021, c. 305, §3(NEW).] [2021, c. 305, §3(NEW).]
4.Pricing component data. "Pricing component data" means data unique to each manufacturer, wholesale drug distributor or pharmacy benefits manager subject to this subchapter that evidences the cost to each manufacturer, wholesale drug distributor or pharmacy benefits manager to make a prescription drug available to consumers and the payments received by each manufacturer, wholesale drug distributor or pharmacy benefits manager to make a prescription drug available to consumers, taking into account any price concessions, and that is measured uniformly among the entities, as determined by rules adopted by the organization pursuant to section 8737. [2019, c. 470, §8(NEW).]
5.Pricing unit. "Pricing unit" means the smallest dispensable amount of a prescription drug that could be dispensed. [2019, c. 470, §8(NEW).]
6.Wholesale acquisition cost. "Wholesale acquisition cost" means a manufacturer's listed price for sale to a wholesale drug distributor or other entity that purchases a prescription drug directly from the manufacturer, not including any price concessions. [2019, c. 470, §8(NEW).]
Amended by 2024, c. 610,§ 2, eff. ninety days following adjournment of the 2024 legislature.Amended by 2024, c. 610,§ 1, eff. ninety days following adjournment of the 2024 legislature.Amended by 2021SP1, c. 305,§ 3, eff. 10/18/2021.Amended by 2021SP1, c. 305,§ 2, eff. 10/18/2021.Amended by 2021SP1, c. 305,§ 1, eff. 10/18/2021.Added by 2019, c. 470,§ 8, eff. 9/19/2019.This section is set out more than once due to postponed, multiple, or conflicting amendments.